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mains elusive. It fortunately remains—as Argile´s and We would also note that in our experience the use
Mourad rightly point out—a topic for further interesting of brachial AV fistulae is associated with a substantial
and challenging studies. incidence of hand ischemia, particularly in diabetic pa-
tients. A policy of using primary brachial AV fistulae in
women, diabetics, and older patients as suggested byChristian Garbar, Michel Jadoul, Henri Noe¨l, and
Miller et al might produce significant complication rates.Charles van Ypersele de Strihou
Department of Pathology, A.Z. VUB, Brussels, Belgium David J. Hirsch and Kailash K. Jindal
Halifax, Canada
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adequacy We thank Drs. Hirsch and Jindal for their thoughtful
response to our publication [1].To the Editor: We were distressed by the conclusions
First, our definition of AV fistula adequacy was notof the recently published paper by Miller et al, “Pre-
totally arbitrary, but rather based on our ability to pro-dictors of adequacy of arteriovenous fistulas in hemodial-
vide adequate dialysis in a reasonable period of time.ysis patients” [1]. These authors defined an adequate
For many of our patients it was not possible to deliverarteriovenous (AV) fistula as the ability to use it for
the minimal Kt/V of 1.2 (as recommended by the NKF-hemodialysis with two needles and a blood flow of at
DOQI guidelines), with a dialysis blood flow of 200 toleast 350 mL/min on at least six dialysis sessions in one
300 mL/min, unless the dialysis time was increased sub-month. Using that definition, they drew the conclusion
stantially. At our dialysis units, it is challenging to con-that only 46.5% of fistulas develop sufficiently to be
vince many of our patients to dialyze longer than 3.5useful. They also noted that the adequacy rate was lower
hours, and exceedingly difficult to get them to stay longerin older patients and those with diabetes.
than 4 hours. Thus, settling for a low blood flow in aWe believe that there are two problems with the con-
marginal fistula in a patient who won’t dialyze longerclusions drawn by these workers.
would mean settling for suboptimal dialysis.First, this definition of AV fistula adequacy is arbi-
Second, Beathard’s study evaluated the outcomes onlytrary, although it has been used by others [2]. By increas-
for those fistulas that were referred for evaluation. Thereing the duration of dialysis, it is often possible to achieve
is no indication of how many fistulas clotted early beforeadequate dialysis clearance at blood flows less than 350
a diagnostic workup could be initiated or what propor-mL/min. This study does not report information on clear-
tion of poorly developed fistulas was referred for anance or dialysis adequacy in any of the patients. If one
evaluation. Moreover, 8 of 71 patients who were referredexpects to achieve successful dialysis with arteriovenous
underwent no further evaluation because of an inade-fistulae, it may be necessary to accept lower flow rates
quate inflow. Thus, it is likely that if one considers allwith the use of longer dialysis times.
fistulas that were placed, the salvage rate would haveA second concern with this study is the failure to
been considerably lower than that reported for the se-address the possibility of salvaging inadequate fistulae.
Beathard et al [2] indicate a significant rate of salvage lected population. In contrast, our study evaluated pro-
for inadequately functioning radiocephalic AV fistulae spectively the outcome of every fistula that was con-
using radiographic investigation and further interven- structed. Specifically, of 50 consecutive forearm fistulas
tion. Beathard and colleagues note a substantial rate of that were placed, 33 were inadequate. These included
long-term functional patency after such interventions in 14 which clotted within a few weeks of their placement.
AV fistulae. The other 19 fistulas remained patent but failed to ma-
ture adequately. Ten of these patients underwent a diag-
nostic ultrasound or fistulogram study. In seven cases an
unsuspected stenosis or occlusion of the draining vein 2000 by the International Society of Nephrology
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was detected. In the four cases with vein stenosis that accounted for the failure to show significant difference
underwent angioplasty the fistulas still failed to develop in renal function compared to the control group. None-
adequately. One patient had a complete occlusion of the theless, the degree of proteinuria was significantly less
subclavian vein. In two patients the fistulogram did not in the treatment arm. The main finding from this five-
reveal any anatomic abnormality. year assessment, however, was that patients who stopped
Finally, notwithstanding the theoretical concerns treatment had significantly worse renal function and
about developing hand ischemia with an upper arm fis- were more likely (6 of 14) to progress to end-stage renal
tula, only one of the 51 consecutive patients in our study disease (ESRD) compared to those who continued treat-
receiving such a fistula developed a clinically significant ment (0 of 13).
steal syndrome. Thirty-one of the patients receiving an Clearly, this finding may be criticized for selection
upper arm fistula were diabetic. bias, since patients who opted to continue treatment may
Michael Allon be more compliant and other confounding factors will
The University of Alabama at Birmingham, Room 129, 1809 influence any analysis made with the RCT as we had
Fifth Avenue South, Birmingham, Alabama 35233-6959, USA.
originally cautioned. This also applies to the interpreta-
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We would concur with the authors that cyclophos-Dipyridamole and low-dose
phamide is no longer justified in the management of IgA
nephropathy because of its toxicity. It is because of ourwarfarin without
clinical observations, the findings of the five-year assess-
ment, as well as the experimental evidence of a renopro-cyclophosphamide in
tective role of dypyridamole and warfarin through im-
mune, anti-platelet and anti-thrombotic mechanisms thatthe management of
we proceeded to a RCT using this regimen [6]. This
three-year trial included 21 patients with IgA nephropa-IgA nephropathy
thy and mild renal impairment, 10 patients assigned to
To the Editor: We were most interested to read the treatment with dipyridamole and low-dose warfarin
recent Kidney International article on evidence-based (keeping the thrombotest between 30 and 50%), and 11
recommendations in the management of IgA nephropa- patients to the control group on no treatment. At the
thy by Nolin and Courteau [1]. Recommendation 2 end of the trial, renal function remained stable in patients
(grade A) states that treatment with cyclophosphamide, on treatment while a significant deterioration was seen
dipyridamole, and warfarin should not be used. This is in the control group. This study suggests that treatment
based on the results from two randomized controlled of patients with IgA nephropathy and renal impairment
trials (RCT), our own three-year study [2], and that of with dipyridamole and low-dose warfarin retards the de-
Walker et al [3], as well as our five-year post-trial assess- terioration in renal function.
ment [4], concern about the absence of post-treatment Walker et al showed reduction in proteinuria over a
biopsy data, and the potential toxicity from cyclophos-
two-year period but, unlike our original study using the
phamide.
same triple regimen and the subsequent trial withoutThe authors correctly state that we were able to dem-
cyclophosphamide, failed to show any beneficial effectonstrate reduction in proteinuria and stabilization in re-
on renal function [3]. The reasons for this difference maynal function at the end of the three-year trial. However,
be related to the shorter duration of treatment (2 yearsthe apparent loss of benefit on renal function at the five-
vs. 3 years) and the use of warfarin at the higher “anti-year post-trial assessment has been misinterpreted and
coagulant doses” (keeping thrombotest between 7 andneeds to be qualified. Only half the patients in the treat-
15%).ment group remained on treatment with dipyridamole
Currently there is no therapy that will cure IgA ne-and low-dose warfarin at five years, which may have
phropathy. It is the most common form of glomerulone-
phritis worldwide, and is especially frequent in the East
among the Chinese and Japanese and an important cause
of ESRD. While we agree with Nolin and Courteau that 2000 by the International Society of Nephrology
